Clinical approaches to minimize rash associated with EGFR inhibitors.

PURPOSE/OBJECTIVES To present a systematic approach for managing the skin rash associated with epidermal growth factor receptor (EGFR)-targeted therapies. DATA SOURCES Clinical research literature, published abstracts, and clinical experience. The approach presented in this article is based on a combination of clinical experience and consultations with dermatologists, oncologists, and pharmacists familiar with EGFR inhibitor-associated rash. DATA SYNTHESIS A proactive approach that includes patient education and the use of a grade-based treatment algorithm. The goal of the approach is to minimize the effects of the rash on patients' quality of life and the course of cancer treatment. CONCLUSIONS Using the approach described in this article to treat the rash associated with the use of EGFR inhibitors, nurses can lessen patient discomfort and help ensure that patients will continue cancer treatment for as long as necessary. IMPLICATIONS FOR NURSING The approach described in this article should help nurses to recognize, grade, and treat the skin rash associated with EGFR inhibitors.